bacampicillin and Chronic-Disease

Topics: Ampicillin; Bronchitis; Chronic Disease; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Haemophilus Infections; Humans

Topics: Adult; Aged; Ampicillin; Bronchitis; Chronic Disease; Clinical Trials as Topic; Female; Haemophilus influenzae; Humans; Male; Middle Aged; Sputum; Time Factors

Topics: Amoxicillin; Ampicillin; Bronchitis; Chronic Disease; Humans; Respiratory Tract Infections; Spain

Topics: Acute Disease; Adolescent; Adult; Aged; Ampicillin; Chronic Disease; Female; Humans; Laryngitis; Lymphadenitis; Male; Middle Aged; Otitis Externa; Pharyngitis; Sinusitis; Tonsillitis

Topics: Adult; Ampicillin; Bronchitis; Chronic Disease; Humans; Kinetics; Middle Aged

The purpose of the study was to select the minimum effective dose of bacampicillin in a systematic dose-response study in hospitalised patients with acute exacerbations of chronic bronchitis. In all 37 patients Haemophilus influenzae or H. parainfluenzae was isolated from purulent sputum before treatment with 400, 800 or 1200 mg of bacampicillin twice daily for 10 days. There was a significant relationship between the administered dose and clinical results at the end of treatment (P less than 0.01) as well as 1 week later (P less than 0.02). The results show that bacampicillin given twice daily is effective in the treatment of acute bacterial exacerbations of chronic bronchitis, with a minimum effective dose of 800 mg twice daily. A rash was noted in one patient.

Topics: Ampicillin; Bronchitis; Chronic Disease; Dose-Response Relationship, Drug; Haemophilus Infections; Humans; Microbial Sensitivity Tests; Sputum

In an open multicentre study of bacampicillin (Penglobe), a new orally well absorb ed prodrug of ampicillin, 516 patients with acute exacerbations of chronic bronchitis or pneumonia were treated by a group of Belgian pneumologists or internists. Bacampicillin was given in a dosage regimen of 400 mg or 800 mg three times daily. In patients with acute exacerbations of chronic bronchitis the clinical success rate was high, over 95% in both groups. An improvement in the sputum purulence score was seen in 93% of the patients with an initially purulent sputum and 69% had a normal mucoid sputum at follow-up. The clinical success rate in patients with pneumonia was also similar in both dosage groups with success rates over 96%. The total number of patients with adverse reactions was not more than 5-4%, of which the majority were considered mild or moderate. Each type of side-effect occurred in a frequency of 1-2% or less. There were no differences between the two dosage regiments as regards the frequency of side-effects indicates a remarkably good tolerance of bacampicillin also with the higher dosage.

Topics: Acute Disease; Adult; Aged; Ampicillin; Bronchitis; Chronic Disease; Female; Humans; Male; Middle Aged; Pneumonia